Previous 10 | Next 10 |
Highlights That Stockholders Have Voted to Re-Elect Steven A. Kriegsman and Dr. Louis Ignarro to the Board Releases New Presentation Summarizing the Company’s Strategic Priorities and Path to Delivering Long-Term Value for Stockholders CytRx Corporation (OTCQB: CYTR) (...
Accelerates Plans to Enhance its Board Composition by Committing to Add a New Independent Director Following a Professionally-Managed Search Process that Includes Stockholder Input Augments Existing Cost Reduction Efforts by Capping Management Compensation and Director Fees at Their...
Exposes Dissident as a “Frivolous Litigant” with a Highly-Questionable Background and Documented History of Poor Judgement Highlights Dissident’s Efforts to Smear CytRx and Misrepresent his Qualifications, Including by Withholding Information from Stockholders R...
LOS ANGELES , Aug. 10, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has mailed a letter to stockholders in connection wit...
Thinly traded nano cap CytRx ( OTCQB:CYTR -1.3% ) is down out the gate this morning on the heels of its announcement that Orphazyme A/S has completed its rolling U.S. marketing application seeking approval of arimoclomol for the treatment of Niemann-Pick disease type-C , a rare inh...
LOS ANGELES , July 21, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have completed their rolling submissio...
LOS ANGELES , July 20, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S announced it will join The Michael J. Fox Fo...
CytRx ( OTCQB:CYTR +4.3% ) highlights that Orphayzme announces topline results of Phase 2 dose-finding study with arimoclomol in Gaucher disease (buildup of certain fatty substances in certain organs); In 2011, CytRx sold the rights to arimoclomol to Orphazyme. More ne...
LOS ANGELES , June 29, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced topline results of their Phase 2 dose-...
LOS ANGELES , June 1, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have initiated the submission of t...
News, Short Squeeze, Breakout and More Instantly...
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...
Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...